1. Through Thick and Thin

3. Program Goal

4. AF and Weight

5. Facts About Overweight and Obesity

6. Weight as a Risk Factor for AF

7. Distribution of BMI (kg/m2) in ENGAGE-AF

8. Efficacy and Safety by BMI Category

9. Case Patient With Obesity

10. Clinical Implications of NOAC Dosing in Extremes of Weight

11. Weight Extremes for NOACs

12. Concerns About Dosing in Underweight Patients

13. Edoxaban in Patients at Risk of Falling

14. "Risk for Falls" in ENGAGE-AF

15. Patients With an Increased Risk for Falls Select Efficacy and Safety Endpoints

16. Absolute Risk Reduction of Edoxaban vs Warfarin in Patients at Risk of Falling

17. Dose Reduction in NOAC Trials

18. NOAC Dosing Recommendations for Body Weight Extremes

19. Take-Home Messages